Date: Sep 12, 2013 Author: Staff Source: bizjournals (
click here to go to the source)
Baltimore biopharmaceutical company Cerecor Inc. said Thursday it closed a $6.8 million round of financing.
That brings to $30 million the total amount of money the company's raised since its 2011 launch. Cerecor will use the fresh funding — what it called a Series A-1 preferred stock financing — for working capital and to complete a tech transfer deal for a possible depression treatment, as well as a licensing agreement with Merck.
"We are delighted by the response to our offering, as it continues to confirm the quality of our company, our pipeline and our team," said Dr. Blake M. Paterson, co-founder and CEO of Cerecor, in a statement.
Cerecor focuses on discovering, developing and commercializing prescription drugs for the human nervous system. Paterson is the former head of Baltimore-based Alba Therapeutics.
